Dyne Therapeutics (DYN) PT Raised to $35 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DYN Hot Sheet
Price: $18.05 --0%
Rating Summary:
16 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
16 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
RBC Capital analyst Luca Issi raised the price target on Dyne Therapeutics (NASDAQ: DYN) to $35.00 (from $30.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Modine Manufacturing (MOD) PT Lowered at KeyBanc on 'Margin Headwinds'
- Rhythm Pharmaceuticals (RYTM) PT Lowered to $146 at Morgan Stanley
- Amgen (AMGN) PT Raised to $520 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
